Comparing HIV viral load assays and frequency of low level virological rebound in clinical practice

International Journal of STD and AIDS

Volumn 25, Issue 14, 2014, Pages 1029-1034

  Briggs, R ^a   Templeton, K ^b   Fernando, I ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c NHS LOTHIAN   (United Kingdom)

Author keywords

AIDS; antiretroviral therapy; blips; HIV; low level virological rebound; treatment; viral load monitoring

Indexed keywords

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; MONITORING; NONHUMAN; REBOUND; VIRUS LOAD; BLOOD; DIAGNOSTIC KIT; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; INCIDENCE; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; MOLECULAR DIAGNOSIS; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VIROLOGY;

DIAGNOSTIC KIT; TAQ POLYMERASE; VIRUS RNA;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TAQ POLYMERASE; VIRAL LOAD;

EID: 84921465800     PISSN: 09564624     EISSN: 17581052     Source Type: Journal    
DOI: 10.1177/0956462414528313     Document Type: Article

References (33)

1. Ruelle J,Debaisieux L,Vancutsem E, et al.HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability.BMC Infect Dis. 2012;12:100-100
2. Pas S,Rossen JWA,Schoener D, et al.Performance evaluation of the new Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 for quantification of human immunodeficiency virus type 1 RNA.J Clin Microbiol. 2010;48:1195-1200
3. Mira JA,Macias J,Nogales C, et al.Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure.Antivir Ther. 2002;7:251-256
4. Nettles RE,Kieffer TL,Kwon P, et al.Intermittent HIV-1 viraemia and drug resistance in patients receiving HAART.JAMA. 2005;293:817-829
5. Gunthard HF,Wong JK,Spina CA, et al.Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy.J Infect Dis. 2000;181:522-531
6. Kolber MA,Gabr AH,De La Rosa A, et al.Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads.AIDS. 2002;16:537-542
7. Ramratnam B,Mittler JE,Zhang L, et al.The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.Nat Med. 2000;6:82-85
8. Smit E,Bhattacharya S,Osman H, et al.Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplicor to Cobas Taqman Assay.J Acquir Immune Defic Syndr. 2009;51:364-385
9. Havlir DV,Bassett R,Levitan D, et al.Prevalence and predictive value of intermittent viremia with combination HIV therapy.JAMA. 2001;286:171-179
10. Sklar PA,Ward DJ,Baker RK, et al.Prevalence and clinical correlates of HIV viremia (“blips”) in patients with previous suppression below the limits of quantification.AIDS. 2002;16:2035-2041
11. Easterbrook PJ,Ives N,Waters A, et al.The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to <400 copies/mL.AIDS. 2002;16:1521-1527
12. Grennan JT,Loutfy MR,Su D, et al.Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis.J Infect Dis. 2012;205:1230-1238
13. Geretti AM,Smith C,Haberl A, et al.Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.Antivir Ther. 2008;13:927-936
14. Gatanaga H,Tsukada Km Honda H, et al.Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor.Clin Infect Dis. 2009;48:260-262
15. Manavi K.The significance of low-level plasma HIV viral load on COBAS TaqMan HIV-1 assays for patients with undetectable plasma viral load on COBAS Amplicor monitor version 1.5.HIV Clin Trials. 2008;9:283-286
16. Lima V,Harrigan R,Montaner JS.Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay.J Acquir Immune Defic Syndr. 2009;51:3-6
17. Karasi JC,Dziezuk F,Quennery L, et al.High correlation between the Roche COBAS® AmpliPrep/COBAS® TaqMan® HIV-1, v2.0 and the Abbott m2000 RealTime HIV-1 assays for quantification of viral load in HIV-1 B and non-B subtypes.J Clin Virol. 2011;52:181-186
18. Yan CS,Hanafi I,Kelleher AD, et al.Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification.J Clin Virol. 2010;49:249-253
19. van Rensburg EJ,Tait K,Watt A, et al.Comparative evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 version 2 test using the TaqMan 48 analyzer and the Abbott RealTime HIV-1 Assay.J Clin Microbiol. 2011;49:377-379
20. Sire JM,Vray M,Merzouk M, et al.Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays.J Acquir Immune Defic Syndr. 2011;56:239-243
21. Wojewoda CM,Spahlinger T,Harmon ML, et al.Comparison of Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 (CAP/CTM v2.0) with other real-time PCR assays in HIV-1 monitoring and follow-up of low-level viral loads.J Virol Meth. 2013;187:1-5
22. Garrett NJ,Apea V,Nori A, et al.Comparison of the rate and size of HIV-1 viral load blips with Roche COBAS TaqMan HIV-1 versions 1.0 and 2.0 and implications for patient management.J Clinical Virol. 2012;53:354-355
23. Kuyper LM,Wood E,Montaner JS, et al.Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort.J Acquir Immune Defic Syndr. 2004;37:1470-176
24. Philips AN,Lundgren JD,Ledergerber B, et al.Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.AIDS. 2004;18:1795-1804
25. Smith CJ,Philips AN,Hill T, et al.The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study.J Infect Dis. 2005;192:1387-1397
26. Maggiolo F,Callegaro A,Cologni G, et al.Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure.J Acquir Immune Defic Syndr. 2011;60:473-482
27. Henrich TJ,Wood BR,Kuritzkes DR.Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 Copies/ml.PLoS One. 2012;7:e50065-e50065
28. Charpentier C,Landman R,Laouénan C, et al.Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome.J Antimicrob Chemother. 2012;67:2231-2235
29. Doyle T,Smith C,Vitiello P, et al.Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy.Clin Infect Dis. 2012;54:724-732
30. Estevez MA,Porcuna NC,Suay VG, et al.Quantification of viral loads lower than 50 copies per milliliter by use of the Cobas AmpliPrep/Cobas TaqMan HIV-1 test, version 2.0, can predict the likelihood of subsequent virological rebound to >50 Copies per milliliter.J Clin Microbiol. 2013;51:1555-1557
31. Widdrington J,Payne B,Medhi M, et al.The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART.J Infect. 2011;62:87-92
32. Doyle T,Geretti AM.Low-level viraemia on HAART: significance and management.Curr Opin Infect Dis. 2012;25:17-25
33. Gandhi RT,Deeks SG.Editorial commentary: editor's choice: plasma HIV-1 RNA levels during antiretroviral therapy: how low is low enough?.Clin Infect Dis. 2012;54:733-735